High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic

International Journal of Drug Policy

Volumn 47, Issue , 2017, Pages 196-201

  Norton, Brianna L ^a   Fleming, Julia ^a   Bachhuber, Marcus A ^a   Steinman, Meredith ^b   DeLuca, Joseph ^a   Cunningham, Chinazo O ^a   Johnson, Nirah ^c   Laraque, Fabienne ^c   Litwin, Alain H ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

^c NEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

Author keywords

Direct acting antivirals (DAAs); Hepatitis C virus (HCV); Opioid agonist therapy (OAT); People who use drugs (PWUD); Real world efficacy

Indexed keywords

ANTIVIRUS AGENT; INTERFERON; LEDIPASVIR PLUS SOFOSBUVIR; OPIATE AGONIST; PEGINTERFERON; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; NARCOTIC ANALGESIC AGENT;

ADULT; ANTIVIRAL THERAPY; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HEALTH CARE ACCESS; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; NEW YORK; OPIATE ADDICTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME; TREATMENT RESPONSE; URBAN AREA; AGED; COMBINATION DRUG THERAPY; COMPLICATION; CONTROLLED CLINICAL TRIAL; DRUG USE; HEALTH SERVICE; MIDDLE AGED; PRIMARY HEALTH CARE;

AGED; ANALGESICS, OPIOID; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; DRUG USERS; FEMALE; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; OPIOID-RELATED DISORDERS; PRIMARY HEALTH CARE; SUSTAINED VIROLOGIC RESPONSE; URBAN HEALTH SERVICES;

EID: 85028324667     PISSN: 09553959     EISSN: 18734758     Source Type: Journal    
DOI: 10.1016/j.drugpo.2017.07.021     Document Type: Article

References (30)

1. Alavi, M., Grebely, J., Micallef, M., Dunlop, A.J., Balcomb, A.C., Day, C.A., Enhancing Treatment for Hepatitis C in Opioid Substitution Settings (ETHOS) Study Group, Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS study. Clinical Infectious Diseases 57:Suppl. 2 (2013), S62–S69, 10.1093/cid/cit305.
2. Alavi, M., Raffa, J.D., Deans, G.D., Lai, C., Krajden, M., Dore, G.J., Grebely, J., Continued low uptake of treatment for hepatitis C virus infection in a large community-based cohort of inner city residents. Liver International 34:8 (2014), 1198–1206, 10.1111/liv.12370.
3. Arora, S., Thornton, K., Murata, G., Deming, P., Kalishman, S., Dion, D., Qualls, C., Outcomes of treatment for hepatitis C virus infection by primary care providers. The New England Journal of Medicine 364:23 (2011), 2199–2207, 10.1056/NEJMoa1009370.
4. Barua, S., Greenwald, R., Grebely, J., Dore, G.J., Swan, T., Taylor, L.E., Restrictions for medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Annals of Internal Medicine 163:3 (2015), 215–223, 10.7326/M15-0406.
5. Bruggmann, P., Falcato, L., Dober, S., Helbling, B., Keiser, O., Negro, F., Swiss Hepatitis C Cohort Study, Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients. Journal of Viral Hepatitis 15:10 (2008), 747–752, 10.1111/j.1365-2893.2008.01010.x.
6. Davis, G.L., Alter, M.J., El-Serag, H., Poynard, T., Jennings, L.W., Aging of hepatitis C virus (HCV)-infected persons in the United States: A multiple cohort model of HCV prevalence and disease progression. Gastroenterology 138:2 (2010), 513–521, 10.1053/j.gastro.2009.09.067 521.e511–516, S0016-5085(09)01885-X [pii].
7. Dimova, R.B., Zeremski, M., Jacobson, I.M., Hagan, H., Des Jarlais, D.C., Talal, A.H., Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis. Clinical Infectious Diseases 56:6 (2013), 806–816, 10.1093/cid/cis1007.
8. Dore, G.J., Altice, F., Litwin, A.H., Dalgard, O., Gane, E.J., Shibolet, O., C-EDGE CO-STAR Study Group, Elbasvir-Grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: A randomized trial. Annals of Internal Medicine 165:9 (2016), 625–634, 10.7326/M16-0816.
9. Grebely, J., Dore, G.J., Can hepatitis C virus infection be eradicated in people who inject drugs?. Antiviral Research 104 (2014), 62–72, 10.1016/j.antiviral.2014.01.002.
10. Grebely, J., Robaeys, G., Bruggmann, P., Aghemo, A., Backmund, M., Bruneau, J., International Network for Hepatitis in Substance Users, Recommendations for the management of hepatitis C virus infection among people who inject drugs. International Journal of Drug Policy 26:10 (2015), 1028–1038, 10.1016/j.drugpo.2015.07.005.
11. Hagan, H., Pouget, E.R., Williams, I.T., Garfein, R.L., Strathdee, S.A., Hudson, S.M., Ouellet, L.J., Attribution of hepatitis C virus seroconversion risk in young injection drug users in 5 US cities. The Journal of Infectious Diseases 201:3 (2010), 378–385, 10.1086/649783.
12. Hajarizadeh, B., Grebely, J., Martinello, M., Matthews, G.V., Lloyd, A.R., Dore, G.J., Hepatitis C treatment as prevention: Evidence, feasibility, and challenges. The Lancet Gastroenterology & Hepatology 1:4 (2016), 317–327, 10.1016/S2468-1253(16)30075-9.
13. Hernandez, M.D., Sherman, K.E., HIV/hepatitis C coinfection natural history and disease progression. Current Opinion in HIV and AIDS 6:6 (2011), 478–482, 10.1097/COH.0b013e32834bd365.
14. Iversen, J., Grebely, J., Topp, L., Wand, H., Dore, G., Maher, L., Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999–2011. Journal of Viral Hepatitis 21:3 (2014), 198–207, 10.1111/jvh.12129.
15. Kattakuzhy, S.M., Gross, C., Teferi, G., et al. High efficacy of HCV Treatment by primary care providers; the ASCEND study. Paper presented at the conference on retroviruses and opportunistic infections (CROI), Boston, MA, 2016.
16. Klevens, R.M., Hu, D.J., Jiles, R., Holmberg, S.D., Evolving epidemiology of hepatitis C virus in the United States. Clinical Infectious Diseases 55:Suppl. 1 (2012), S3–S9, 10.1093/cid/cis393.
17. Lazarus, J.V., Sperle, I., Maticic, M., Wiessing, L., A systematic review of Hepatitis C virus treatment uptake among people who inject drugs in the European Region. BMC Infectious Diseases, 14(Suppl. 6), 2014, S16, 10.1186/1471-2334-14-S6-S16.
18. Ly, K.N., Xing, J., Klevens, R.M., Jiles, R.B., Ward, J.W., Holmberg, S.D., The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Annals of Internal Medicine 156:4 (2012), 271–278, 10.1059/0003-4819-156-4-201202210-00004 156/4/271 [pii].
19. Mason, K., Dodd, Z., Guyton, M., Tookey, P., Lettner, B., Matelski, J., Powis, J., Understanding real-world adherence in the directly acting antiviral era: A prospective evaluation of adherence among people with a history of drug use at a community-based program in Toronto, Canada. International Journal of Drug Policy 47 (2017), 202–208, 10.1016/j.drugpo.2017.05.025 pii: S0955-3959(17)30129-9.
20. McGinn, T., O'Connor-Moore, N., Alfandre, D., Gardenier, D., Wisnivesky, J., Validation of a hepatitis C screening tool in primary care. Archives of Internal Medicine 168:18 (2008), 2009–2013, 10.1001/archinte.168.18.2009.
21. Melin, P., Chousterman, M., Fontanges, T., Ouzan, D., Rotily, M., Lang, J.P., CheObs Study Group, Effectiveness of chronic hepatitis C treatment in drug users in routine clinical practice: Results of a prospective cohort study. European Journal of Gastroenterology and Hepatology 22:9 (2010), 1050–1057, 10.1097/MEG.0b013e328338d9aa.
22. Morris, L., Smirnov, A., Kvassay, A., Leslie, E., Kavanagh, R., Alexander, N., Najman, J., Initial outcomes of integrated community-based hepatitis C treatment for people who inject drugs: Findings from the Queensland Injectors’ Health Network. International Journal of Drug Policy 47 (2017), 216–220, 10.1016/j.drugpo.2017.05.056 pii: S0955-3959(17)30160-3.
23. Nelson, P.K., Mathers, B.M., Cowie, B., Hagan, H., Des Jarlais, D., Horyniak, D., Degenhardt, L., Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: Results of systematic reviews. Lancet 378:9791 (2011), 571–583, 10.1016/S0140-6736(11)61097-0.
24. Read, P., Lothian, R., Chronister, K., Gilliver, R., Kearley, J., Dore, G.J., van Beek, I., Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting. International Journal of Drug Policy 47 (2017), 209–215, 10.1016/j.drugpo.2017.05.032 pii: S0955-3959(17)30136-6.
25. Recommendations for Testing, Managing, and Treating Hepatitis C. (2017). Retrieved July 4, 2017, from http://www.hcvguidelines.org.
26. Rein, D.B., Wittenborn, J.S., Weinbaum, C.M., Sabin, M., Smith, B.D., Lesesne, S.B., Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. Digestive and Liver Disease 43:1 (2011), 66–72, 10.1016/j.dld.2010.05.006.
27. Southern, W.N., Drainoni, M.L., Smith, B.D., Christiansen, C.L., McKee, D., Gifford, A.L., Litwin, A.H., Hepatitis C testing practices and prevalence in a high-risk urban ambulatory care setting. Journal of Viral Hepatitis 18:7 (2011), 474–481, 10.1111/j.1365-2893.2010.01327.x.
28. Swan, D., Long, J., Carr, O., Flanagan, J., Irish, H., Keating, S., Cullen, W., Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: A qualitative exploration. AIDS Patient Care and STDS 24:12 (2010), 753–762, 10.1089/apc.2010.0142.
29. Verna, E.C., Brown, R.S. Jr., Hepatitis C virus and liver transplantation. Clinics in Liver Disease 10:4 (2006), 919–940, 10.1016/j.cld.2006.08.012.
30. Williams, I.T., Bell, B.P., Kuhnert, W., Alter, M.J., Incidence and transmission patterns of acute hepatitis C in the United States, 1982–2006. Archives of Internal Medicine 171:3 (2011), 242–248, 10.1001/archinternmed.2010.511.